Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCRαβ+ T cell-depleted hematopoietic stem cells
- Development stage
- Phase 2
- Lead developer
- Miltenyi Biotec
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
TCRαβ+ T cell-depleted hematopoietic stem cells are an ex vivo graft engineering technique used in haplo-hematopoietic stem cell transplantation. This method aims to effectively reduce the risk of graft-versus-host disease (GVHD) by selectively depleting TCRαβ+ T cells from the stem cell graft. The process typically involves magnetic sorting using devices like the CliniMACS® Plus, which allows for thorough depletion of TCRαβ+ T cells while maintaining high yields of CD34+ cells, TCRγδ+ T cells, and NK cells. This approach enables the infusion of mega-dose CD34+ cells, even in higher-weight patients, and has shown high primary engraftment rates.
- Other names
- TCR alpha/beta-depleted HSCTαβ T-cell depleted HSCTTCR alpha/beta/CD19-depleted hematopoietic stem cellsTCRαβ/CD19-depleted HSCT
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on TCRαβ+ T cell-depleted hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCRαβ+ T cell-depleted hematopoietic stem cells.